Oct 21 (Reuters) - Valeant Pharmaceuticals International Inc (N:VRX) VRX.TO :
* Responds to erroneous report
* Says responds to "recent accusations made regarding its financial reporting
and operations"
* 69 million at wholesaler acquisition cost of products shipped by Valeant to
r&o were not recorded as revenue
* Any inventory at pharmacies in philidor pharmacy network included in
valeant's consolidated inventory
* All shipments to philidor, other pharmacies in philidor pharmacy network, are
not recorded in co's consolidated net revenue
* Timing of revenue recognition by selling via philidor harmacy network delayed compared to selling via wholesaler channel
* Source text for Eikon ID:nCNWpZk6ma
* Further company coverage VRX.TO